News Releases

Month Year

Investor Alerts

Apr 22, 2020

Hoth Therapeutics to Host Shareholder Update Conference Call with Dr. Mark Poznansky to Discuss COVID-19 Vaccine Candidate, VaxCelerate

Dr. Poznansky will answer pre-submitted questions from investors at the conclusion of the call

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced hosting a shareholder update conference call with Dr. Mark Poznansky on Thursday, April 23, 2020 at 10:15 a.m....
Apr 21, 2020

Hoth Therapeutics Announces Top Line Preclinical Data from Cutaneous Lupus Erythematosus (CLE) Study

The study conducted in partnership with Zylö Therapeutics confirmed mice treated with Anandamide (AEA)-loaded particles experienced lesions that regressed in size and severity

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced top line data from its Cutaneous Lupus Erythematosus (CLE) study, a chronic autoimmune skin disease, in...
- Photos 1
Apr 17, 2020

Hoth Therapeutics Announces Additions to its Board of Directors

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the addition of two independent members, Mr. Graig Springer and Mr. Wayne Linsley, to its Board of Directors....
Apr 15, 2020

Dr. Mark Poznansky Co-Creator of VaxCelerate Appeared on MSNBC to Discuss COVID-19 Vaccines

Dr. Poznansky serves as both scientific founder and advisory board member of HaloVax, a joint venture between Hoth Therapeutics and Voltron Therapeutics

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Dr. Mark Poznansky, Co-Creator of VaxCelerate, a self-assembling vaccine (SAV) platform, appeared as a...
Apr 9, 2020

Hoth Therapeutics Commences Next Phase of VNLG-152 Study

Solubility and formulation had been established for the drug in the treatment of dermatological diseases

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced initiating the next phase of its study of VNLG-152 novel retinamides (Retinoic acid metabolism blocking agents...
Apr 2, 2020

Hoth Update on HaloVax Partnership Vaccine to Fight COVID-19 with Sponsored Research Agreement with the Vaccine and Immunotherapy Center (VIC) of the Massachusetts General Hospital (MGH)

Collaboration aims to accelerate candidate development and animal model testing of HaloVax Self-Assembling Vaccine to fight Coronavirus COVID-19

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced its joint venture entity with Voltron Therapeutics, Inc., HaloVax, has entered into a Sponsored Research...
Mar 30, 2020

Hoth Therapeutics Enters into Letter of Intent with Isoprene Pharmaceuticals, Inc. to License VNLG-152 for Treatment of Dermatological Diseases

Hoth to receive equity stake in Isoprene, full license of VNLG 152 for field of Dermatology and royalties from Isoprene for all other fields including Oncology

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has entered into a non-binding letter of intent ("LOI") with Isoprene Pharmaceuticals, Inc. to acquire the...
Mar 24, 2020

Hoth Announces Pricing of $5 Million Public Offering of Common Stock

Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("Hoth" or the "Company"), a biopharmaceutical company, today announced the pricing of its previously announced "best efforts" underwritten public offering...
Mar 23, 2020

Hoth Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Hoth Therapeutics Inc. (Nasdaq: HOTH) ("Hoth" or the "Company"), a biopharmaceutical company, today announced that it intends to offer shares of its common stock in a "best efforts" underwritten...
Mar 23, 2020

Hoth Therapeutics Announces Agreement to Joint Development for a Self-Assembling Vaccine (SAV) for the Potential Prevention of the Coronavirus (COVID-19)

The SAV technology has been exclusively licensed from Massachusetts General Hospital

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has reached an agreement with Voltron Therapeutics, Inc. (Voltron) to form a joint venture entity, to be...
Mar 23, 2020

Hoth Therapeutics Announces Agreement to Joint Development of a Self-Assembling Vaccine (SAV) for the Potential Treatment of the Coronavirus (COVID-19)

The SAV technology has been exclusively licensed from Massachusetts General Hospital

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has reached an agreement with Voltron Therapeutics, Hoth Therapeuticsto form a joint venture entity (to be...
Mar 19, 2020

Hoth Therapeutics Announces Positive Preclinical Data of WEG232 Treatment, Developed for Cancer Patients Suffering from Erlotinib-Induced Facial Dermatitis and Hair Loss

WEG232 topical treatment showed a 71% reduction in SD-Rats with erlotinib-induced facial rash/hair loss

Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the "Company' or "Hoth"), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging...
Mar 16, 2020

Diamond Equity Research Publishes Report Valuing HOTH Common Stock at $7.00 Per Share

Diamond Equity Research, an equity research firm with a focus on micro capitalization and small capitalization public companies has released a comprehensive update note of Hoth Therapeutics, Inc....
Mar 9, 2020

Hoth Therapeutics, Inc. States COVID-19 Coronavirus Poses No Negative Effect on Company's Operations

Atopic Dermatitis sufferers are reminded by the National Eczema Society that there is no eczema-friendly hand sanitizer, as they all contain alcohol, which dries out the skin

Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis,...
Feb 19, 2020

Hoth Therapeutics Receives Notice of Allowance from European Patent Office

Validations in France, Germany, Spain and the United Kingdom

Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis,...
Feb 12, 2020

Hoth Therapeutics Announces Positive Preliminary, Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease

The study conducted in partnership with Zylö Therapeutics confirmed AEA-loaded in Z-pods™ provides an actual reduction in lesion score

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis,...
- Photos 1
Feb 11, 2020

Hoth Therapeutics, Inc. to Present at 2020 Noble Capital Market's Sixteenth Annual Small-Cap Investor Conference

Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis,...
Feb 4, 2020

Hoth Initiates Preclinical Gene Therapy Program with NC State for the Treatment of Asthma and Allergic Inflammation

Hoth appoints Dr. Glenn Cruse, formerly of the NIH and a leading mast cell biologist in allergic and inflammatory diseases, to the Scientific Advisory Board

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis,...
Jan 29, 2020

Hoth Therapeutics to Further its Research of VNLG-152 and Plans Exercise of its Option Agreement with University of Maryland, Baltimore and Isoprene Pharmaceuticals Inc.

Preclinical work is now underway at Weill Cornell Medicine to examine the efficacy of RAMBA in blocking acne pathogenic gene expression and carcinogenesis in mice

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing new generation therapies for dermatological and immunological disorders such as atopic dermatitis,...
Jan 21, 2020

Hoth Completes Animal Safety Study of Proprietary BioLexa Platform for the Treatment of Atopic Dermatitis

All animals were in good condition with no adverse safety effects during the study

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing new generation therapies for dermatological and immunological disorders such as atopic dermatitis,...
Jan 15, 2020

Hoth Therapeutics Exercises Patent Licensing Option with the George Washington University to Further Develop a Therapeutic for Cancer Patients Suffering Cutaneous Changes Like Rash and Hair Loss, as Well as Other Neurogenic Inflammation Side Effects

Preclinical results showed Substance P receptor blocker, inhibited cutaneous and other neurogenic inflammation side effects of the Anticancer EGFR-TKI, erlotinib

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis,...
Dec 23, 2019

Hoth Therapeutics, Inc. Issues 2019 Shareholder Letter

Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological and immunological disorders such as...
Dec 19, 2019

Hoth Therapeutics Enters into Research Collaboration Agreement with Weill Cornell Medicine to Examine the Efficacy of RAMBA in Blocking Acne Pathogenic Gene Expression

Research will be conducted in three phases examining human keratinocyte cells, mouse skin and carcinogenesis in mice

Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis,...
Dec 17, 2019

Hoth Therapeutics Announces the Appointment of Dr. William Weglicki, M.D. to Scientific Advisory Board

Dr. Weglicki to oversee Hoth's Aprepitant Program under Scientific Research Agreement with the George Washington University

Hoth Therapeutics, Inc. (NASDAQ: HOTH), ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic...
Dec 9, 2019

Hoth Therapeutics And North Carolina State University Initiate Preclinical Gene Therapy Study For The Treatment Of Asthma

Dr. Glenn Cruse, a leading mast cell biologist in allergic and inflammatory diseases, will lead the preclinical development of Splice-switching oligonucleotides (SSOs) for asthma

Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis,...

Show per page

INVESTORS

News Releases